Your session is about to expire
← Back to Search
Satralizumab for Thyroid Eye Disease (SatraGO-2 Trial)
SatraGO-2 Trial Summary
This trial studies the effects of an anti-IL-6 antibody on people with thyroid eye disease.
SatraGO-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSatraGO-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 85 Patients • NCT02028884SatraGO-2 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has Satralizumab been sanctioned by the Food and Drug Administration?
"Satralizumab's efficacy has been established in prior studies, leading to it being rated 3 out of a possible 3 for safety. Multiple rounds of data have supported this evaluation."
How many participants are being recruited for the research study?
"Affirmative. Information hosted on clinicaltrials.gov reveals that the trial, which was first posted on November 15th 2023, is currently enrolling patients. A total of 120 participants are needed to be recruited from 6 different research centres."
In what geographical locations is this research project being conducted?
"There are 6 medical centres offering this trial such as the Scheie Eye Institute in Philadelphia, Beijing Hospital of Ministry of Health in Beijing, and Peking University Third Hospital in Xi'an City."
Are there any vacancies left for participants in this research project?
"Affirmative. Clinicaltrials.gov's records indicate that this clinical trial is actively enrolling patients, which has been listed since November 15th 2023 and was last updated on December 1st 2023. The experiment seeks to enlist 120 people from 6 different sites."
Share this study with friends
Copy Link
Messenger